1. Administration FaD (2011) FR Vol 76 Issue 4 – 76 FR 789 – Guidance for Industry and Food and Drug Administration Staff; Section 905(j) Reports: Demonstrating Substantial Equivalence for Tobacco Products; Availability. U. F. a. D. Administration. Washington, DC, The Archives of the United States 76, 789–790
2. Administration FaD (2012) 77 FR 20030 – reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance 77
3. Armitage AK, Dixon M, Frost BE, Mariner DC, Sinclair NM (2004) The effect of inhalation volume and breath-hold duration on the retention of nicotine and Solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking. Beiträge zur Tabakforschung international/contributions to tobacco research. 21, 240
4. Auerbach O, Stout AP, Hammond EC, Garfinkel L (1961) Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 265:253–267
5. Bell KA (1978) Deposition in respiratory airway models. Recent Develop Aerosol Sci